- Category: HCV Treatment
- Published on Wednesday, 06 May 2015 00:00
- Written by Liz Highleyman
A 6-week regimen of sofosbuvir (Sovaldi) plus 2 experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver cirrhosis, according to a poster presentation at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. A 4-week regimen was not effective for any group, however, and 6 weeks appears inadequate for harder-to-treat patients. Other studies showed that the new drugs -- GS-5816 (velpatasvir) and GS-9857 -- are also active against other HCV genotypes.